Sporotrichosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 13: | Line 13: | ||
|Uncomplicated cutaneous | |Uncomplicated cutaneous | ||
|Itraconazole [200 mg/day] | |Itraconazole [200 mg/day] | ||
|Itraconazole [200 b.i.d.], terbinafine [500 b.i.d.], SSKI [increasing doses], fluconazole [400-800 mg/day], or local hyperthermia | |Itraconazole [200 mg b.i.d.], terbinafine [500 b.i.d.], SSKI [increasing doses], fluconazole [400-800 mg/day], or local hyperthermia | ||
|Continue treatment for 2-4 weeks after lesions resolve. | |Continue treatment for 2-4 weeks after lesions resolve. | ||
|- | |- | ||
Revision as of 13:45, 13 January 2016
|
Sporotrichosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sporotrichosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Sporotrichosis medical therapy |
|
Risk calculators and risk factors for Sporotrichosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alison Leibowitz [2]
Treatment
| Form | Primary Line of Treatment | Alternative Treatment | Remarks/Other |
|---|---|---|---|
| Uncomplicated cutaneous | Itraconazole [200 mg/day] | Itraconazole [200 mg b.i.d.], terbinafine [500 b.i.d.], SSKI [increasing doses], fluconazole [400-800 mg/day], or local hyperthermia | Continue treatment for 2-4 weeks after lesions resolve. |
| Osteoarticular | Itraconazole [200 mg b.i.d.] | Limposomal amphotericin B [3-5 mg/kg/day] or deoxycholate amphotericin B [0.7-1 mg/kg/day] until symptom resolution | For a total of 12 months, switch to itraconazole after resolution/end of treatment. |
| Pulmonary | Limposomal amphotericin B [3-5 mg/kg/day], followed by itraconazole [200 mg b.i.d.] | Deoxycholate amphotericin B [0.7-1 mg/kg/day], followed by itraconazole [200 mg b.i.d.] upon symptom resolution | Treat less sever cases with a 12 month regimen of itraconazole. |
| Meningeal | Limposomal amphotericin B [3-5 mg/kg/day], followed by itraconazole [200 mg b.i.d.] | Deoxycholate amphotericin B [0.7-1 mg/kg/day], followed by itraconazole [200 mg b.i.d.] upon symptom resolution | Precise length of amphotericin B treatment varies. Suppressive treatment with itraconazole is necessary. |
| Dissimated | Limposomal amphotericin B [3-5 mg/kg/day], followed by itraconazole [200 mg b.i.d.] | Deoxycholate amphotericin B [0.7-1 mg/kg/day], followed by itraconazole [200 mg b.i.d.] upon symptom resolution | Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with itraconazole is necessary. |
| Sporotrichosis in pregnant women | Treat with limposomal amphotericin B [3-5 mg/kg/day] or deoxycholate amphotericin B [0.7-1 mg/kg/day] only for severe cases of sporotrichosis.
In cases of uncomplicated cutaneous, treat with only hyperthermia. |
It is preferable to defer treatment in uncomplicated cases. | |
| Sporotrichosis in Children | Itraconazole [6-10 mg/day to a max of 400 mg] for mild cases
Deoxycholate amphotericin B [0.7-1 mg/kg/day] for severe cases |
SSKI [increasing doses equivalent to half the adult dose], continuing treatment for 2-4 weeks after resolution of symptoms. | |
References
- ↑ Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.